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Among other aspects it is the communication which makes
the difference between a crowd of individuals and a society.
Similarly, a key feature of an organism or of organs is the com-
munication between their individual cells realized by mediators,
hormones, and by direct intercellular communication via gap
junction channels allowing the transmission of electrical signals
and the exchange of small molecules to regulate growth and dif-
ferentiation. This enables the organ or the organism to adapt
very efficiently to the actual needs. Due to the important role
of gap junction intercellular communication (GJIC) for the cor-
rect functioning of organs, and tissues a tight regulation of the
expression of gap junction channel proteins, the connexins, their
localization, and function is required. Besides connexins, another
group of proteins, the pannexins, showing many molecular simi-
larities with connexins have been identified. They seem to form
hemichannels which may regulate cytosolic homeostasis or the
release of small molecules. The present issue provides a compre-
hensive picture of recent developments and current research in
this fascinating, fast developing area comprising review and orig-
inal research articles on both connexins and pannexins written by
leading experts in their research areas. The articles are organized
in three parts:
A: role of gap junctions in cell biology; regulation and targeting
of connexins (11 articles)
B: connexins and pannexins (3 articles)
C: gap junctions in various diseases (6 articles)
Regarding part A, regulation of connexin function is not only
realized via regulation of expression but also by various post-
translational modifications as reviewed by Axelsen et al. (2013).
Verheule and Kaese (2013) shed light on the different roles
of cardiac connexins for cardiac phenotypes in various knock-
out models. Connexins not only form intercellular dodecameric
channels but alsomay form unopposed hemichannels, whichmay
allow cAMP release as a new pathway for intercellular cAMP sig-
naling as shown by Valiunas (2013). With regard to their role in
differentiation and growth Oyamada et al. (2013) review the role
of GJIC and connexins in development and re-programming of
embryonic stem cells and induced pluripotent stem cells in com-
parison to the undifferentiated state. According to recent findings
connexins not only have functions in the membrane, but also
may control gene expression, and -as found by Boengler et al.
(2013)-are expressed in the mitochondria where they control
mitochondrial K+-influx. Another puzzling aspect of gap junc-
tion research is the ability or non-ability of certain connexins to
form heteromeric channels which are composed of more than
only one isoform. Regarding this aspect Beyer et al. (2013a)
investigate the heteromeric interactions between Cx40 and Cx43
focusing on the role of the N-terminal. Regarding growth con-
trol by GJIC Kardami’s group investigated the inhibition of DNA
synthesis by Cx43 and S262-Cx43 de-phosphorylation Jeyaraman
et al. (2013). In the next two articles histone-deacetylase is exam-
ined as a possible pharamcological target for influencing Cx43
expression with reduced expression when using trichostatin A
(Xu et al., 2013) or with enhanced expression when using 4-
phenylbutyrate (Kaufman et al., 2013). The section is closed
with two more methodological articles showing a new cell cul-
ture system for the study of Cx29 (Söhl et al., 2013) and a new
Escherichia coli expression system for Cx45 carboxyl terminus
allowing the yield of large protein amounts as needed for NMR
analysis (Kopanic et al., 2013).
Part B starts with an original article about pannexin 1 elucidat-
ing the problems with Panx1 knock outs and showing the gener-
ation of astrocyte and neuron-specific Panx1 deletions (Hanstein
et al., 2013). The role of Panx1 and connexin hemichannels in
brain glial cells in health and disease as well their impact for neu-
roglial interaction and possible pharmacological approaches are
reviewed by Giaume et al. (2013). The distribution of Panx1 in
four rat brain regions using different antibodies in a comparative
study is investigated by Cone et al. (2013).
Part C focuses on the role of gap junctions in various dis-
eases starting with an interesting hypothesis article by Végh et al.
(2013) on the regulation of cardiac gap junctions by nitric oxide
in ischemia and reperfusion and its relation to arrhythmia. In the
next article the inverse relationship between proliferative activity
of a tumor induced by cardiac transplantation of bone mar-
row stem cells and intra-tumor connexin expression. Spath et al.
(2013) conclude that the lack of connexin expression in the most
proliferative areas of the tumor results in absence of differenti-
ation and growth stop signals so that invasive growth is facili-
tated. The role of gap junction mutations or alteration in inborn
human heart disease is reviewed by Salameh et al. (2013) in com-
parison to the findings in various mouse models. Beyer et al.
(2013b) review the role of connexin mutations in the pathogen-
esis of lens cataracts and discuss altered hemichannel functions
and formation of cytoplasmic accumulations. Interesting new
aspects about a possible pathogenetic role of gap junctions are
given by Blanke et al. (2013) with regard to the formation of
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infantile hemangiomas and possible interference between beta-
adrenoceptors and connexins. The section closes with a review
on the most recent advances in research on GJIC and oculoden-
toglial dysplasia focussing on the possible relationship between
channel dysfunction and neurological symptoms in these patients
De Bock et al. (2013).
This compilation of articles on most recent developments
in connexin and pannexin research hopefully encourages more
scientists to investigate these highly interesting cell biology mech-
anisms in their research areas. When cellular interaction or
interplay is of relevance this recent research suggests: mid the gap!
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